文献速递前列腺癌

1253例前列腺癌初诊分期中68镓-前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描发现转移性疾病的风险

Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer.
PubMed 文献 · BJU Int · 2019-07-02

该回顾性研究纳入2014年7月至2018年6月间1253例初诊前列腺癌患者,行68Ga-PSMA PET/CT分期,旨在确定诊断时转移风险。结果显示12.1%存在转移,PSA、ISUP分级和mpMRI分期均为转移的显著预测因素,支持68Ga-PSMA PET/CT用于初诊分期。

要点

  • 1253例初诊前列腺癌患者中,68Ga-PSMA PET/CT检出转移者占12.1%。
  • PSA<10 ng/mL者转移率8.2%,PSA>20 ng/mL者转移率43%。
  • ISUP 2-3级转移率6.4%,ISUP 4-5级转移率21%。

核心结论

  • 结果支持使用68Ga-PSMA PET/CT进行前列腺癌初诊分期。
  • PSA水平升高、ISUP分级升高和mpMRI影像分期均是转移的独立预后因素,单因素和多因素分析均有统计学显著性。

研究设计与样本

  • 回顾性综述,纳入2014年7月至2018年6月由泌尿科或放射肿瘤科医生转诊至三级转诊中心、初诊前列腺癌行68Ga-PSMA PET/CT分期的1253例连续男性患者。
  • 主要结局指标为基于68Ga-PSMA PET/CT的转移风险;按活检ISUP分级、PSA水平和活检前mpMRI分期进行风险分层;采用单因素和多因素逻辑回归分析。

主要发现

  • 中位PSA为6.5 ng/mL,中位ISUP分级为3,高危疾病占49.7%。
  • 前列腺原发灶PSMA高摄取者占91.7%;转移性疾病检出率为12.1%。
  • PSA<10 ng/mL者转移率8.2%,PSA>20 ng/mL者转移率43%;ISUP 2-3级者转移率6.4%,ISUP 4-5级者转移率21%。
  • 活检前mpMRI T2期疾病转移率8.1%,T3b期增至42.4%;107例疑似淋巴结转移,其中47.7%位于扩大盆腔淋巴结清扫范围之外;骨转移检出率4.7%。
  • 中危前列腺癌患者转移率5.2%,高危患者为19.9%。

临床怎么用

  • 原文结论认为结果支持使用68Ga-PSMA PET/CT进行前列腺癌初诊分期。
  • 原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the number of men with 68 gallium-prostate-specific membrane antigen positron emission tomography/computed tomography (68 Ga-PSMA PET/CT) avid metastasis at diagnosis, as most data on 68 Ga-PSMA PET/CT are for the evaluation of recurrent disease after primary treatment and to our knowledge this study is the largest series of primary prostate cancer staging with 68 Ga-PSMA PET/CT. PATIENTS AND METHODS: A retrospective review conducted on 1253 consecutive men referred by urologists or radiation oncologists to our tertiary referral centre for 68 Ga-PSMA PET/CT scan for staging at the initial diagnosis of prostate cancer between July 2014 and June 2018. The primary outcome measure was to determine the risk of metastasis based on 68 Ga-PSMA PET/CT. Patients were risk stratified based on histological biopsy International Society of Urological Pathology (ISUP) grade, prostate-specific antigen (PSA) level, and staging with pre-biopsy multiparametric magnetic resonance imaging (mpMRI). Univariate and multivariate logistic regression were used to analyse results. RESULTS: The median PSA level was 6.5 ng/mL and median ISUP grade was 3, with high-risk disease in 49.7%. The prostate primary was PSMA avid in 91.7% of men. Metastatic disease was identified in 12.1% of men, including 8.2% with a PSA level of <10 ng/mL and 43% with a PSA level of >20 ng/mL. Metastases were identified in 6.4% with ISUP grade 2-3 and 21% with ISUP grade 4-5. Pre-biopsy mpMRI identified metastasis in 8.1% of T2 disease, increasing to 42.4% of T3b. Lymph node metastases were suspected in 107 men, with 47.7% outside the boundaries of an extended pelvic lymph node dissection. Skeletal metastases were identified in 4.7%. In men with intermediate-risk prostate cancer, metastases were identified in 5.2%, compared to 19.9% with high-risk disease. CONCLUSIONS: These results support the use of 68 Ga-PSMA PET/CT for primary staging of prostate cancer. Increasing PSA level, ISUP grade and radiological staging with mpMRI were all statistically significant prognostic factors for metastasis on both univariate and multivariate analysis.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Yaxley JW, Raveenthiran S, Nouhaud FX, et al. Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int. 2019. PMID: 31141284. doi:10.1111/bju.14828

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。